Market Overview

UPDATE: Piper Jaffray Raises PT to $11 on ISIS Pharmaceuticals on KYNAMRO Approval

Related ISIS
NASDAQ Slides 1.2%; Manitowoc Shares Dip Following Cautious Outlook
Markets Mixed; Fastenal Earnings Meet Estimates
Making Money With Charles Payne: 10/08/14 (Fox Business)

Piper Jaffray maintained ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) with a Neutral rating and raised the price target from $9.00 to $11.00.

Piper Jaffray said, "The FDA approved KYNAMRO for Homozygous Familial Hypercholesterolemia (HoFH). As expected, the approval comes with a Boxed Warning for liver toxicity and a REMS program. ISIS is required to conduct 4 post marketing studies. This approval comes in the wake of the recent negative CHMP opinion for KYNAMRO's marketing authorization application (MAA) and therefore serves as an important validation of ISIS's antisense technology. We maintain our Neutral rating and are increasing our price target to $11 from $9 due to a reduced discount rate following KYNAMRO approval."

ISIS Pharmaceuticals closed at $13.38 on Tuesday.

Latest Ratings for ISIS

DateFirmActionFromTo
Sep 2014Leerink SwannAssumesMarket Perform
Aug 2014BMO CapitalMaintainsOutperform
Aug 2014Laidlow & Co.Initiates Coverage onBuy

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters